The SYT-SSX fusion protein and histological epithelial differentiation in synovial sarcoma: Relationship with extracellular matrix remodeling

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 11, 2013, Pages 2272-2279

  Saito, Tsuyoshi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Chromosomal translocation t(X; 18)(p11.2; q11.2); E cadherin; Epithelial differentiation; Synovial sarcoma; SYT SSX1; SYT SSX2

Indexed keywords

BIOLOGICAL MARKER; CADHERIN; ONCOPROTEIN; SYT SSX FUSION PROTEIN; SYT-SSX FUSION PROTEIN;

ANIMAL; CELL DIFFERENTIATION; CHROMOSOMAL TRANSLOCATION T(X;18)(P11.2;Q11.2); E-CADHERIN; EPITHELIAL DIFFERENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; GENE FUSION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; REVIEW; SYNOVIAL SARCOMA; SYT-SSX1; SYT-SSX2; WNT SIGNALING PATHWAY;

CHROMOSOMAL TRANSLOCATION T(X;18)(P11.2;Q11.2); E-CADHERIN; EPITHELIAL DIFFERENTIATION; SYNOVIAL SARCOMA; SYT-SSX1; SYT-SSX2;

ANIMALS; BIOLOGICAL MARKERS; CADHERINS; CELL DIFFERENTIATION; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE FUSION; HUMANS; ONCOGENE PROTEINS, FUSION; SARCOMA, SYNOVIAL; WNT SIGNALING PATHWAY;

EID: 84887103913     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Weiss SW and Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors. 4th edn. Philadelphia: Mosby, 2001.
2. Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, Gusterson BA and Cooper CS. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994;7:502-508.
3. Nagai M, Tanaka S, Tsuda M, Endo S, Kato H, Sonobe H, Minami A, Hiraga H, Nishihara H, Sawa H and Nagashima K. Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha. Proc Natl Acad Sci USA 2001;98:3843-3848.
4. Kadoch C and Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 2013;153:71-85.
5. Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR and Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998;338:153-160.
6. Antonescu CR, Kawai A, Leung DH, Lonardo F, Woodruff JM, Healey JH and Ladanyi M. Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol 2000;9:1-8.
7. Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, Yoshioka K, Joyama S, Hamada K, Tsukamoto Y, Tomita Y, Ueda T, Yoshikawa H and Itoh K. Synovial sarcoma is a stem cell malignancy. Stem Cells 2010;28:1119-1131.
8. Saito T, Nagai M and Ladanyi M. SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by Snail and Slug. A potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer Res 2006;66:6919-6927.
9. Saito T, Oda Y, Sugimachi K, Kawaguchi K, Tamiya S, Tanaka K, Matsuda S, Sakamoto A, Iwamoto Y and Tsuneyoshi M. E-cadherin gene mutations frequently occur in synovial sarcoma as a determinant of histological features. Am J Pathol 2001;159:2117-2124.
10. Saito T, Oda Y, Kawaguchi K, Sugimachi K, Yamamoto H, Tateishi N, Tanaka K, Matsuda S, Iwamoto Y, Ladanyi M and Tsuneyoshi M. E-cadherin mutation and Snail overexpression as alternative mechanisms of E-cadherin inactivation in synovial sarcoma. Oncogene 2004;23:8629-8638.
11. Sun Y, Sun B, Wang J, Cai W, Zhao X, Zhang S and Hao X. Prognostic implication of SYT-SSX fusion type and clinicopathological parameters for tumor-related death, recurrence, and metastasis in synovial sarcoma. Cancer Sci 2009;100:1018-1025.
12. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, Brennan MF, Bridge JA, Neff JR, Barr FG, Goldsmith JD, Brooks JS, Goldblum JR, Ali SZ, Shipley J, Cooper CS, Fisher C, Skytting B and Larsson O. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma:a multi-institutional retros-pective study of 243 patients. Cancer Res 2002;62:135-40.
13. Guillou L, Benhattar J, Bonichon F, Gallagher G, Terrier P, Stauffer E, Somerhausen Nde S, Michels JJ, Jundt G, Vince DR, Taylor S, Genevay M, Collin F, Trassard M and Coindre JM. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma:a multicenter, retrospective analysis. J Clin Oncol 2004;22:4040-4050.
14. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA. The transcription factor snail controls epithelial-mesenchymal transition by repressing E-cadherin expression. Nat Cell Biol 2000;2:76-83.
15. Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J and García De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000;2:84-89.
16. Saito T, Oda Y, Sakamoto A, Tamiya S, Kinukawa N, Hayashi K, Iwamoto Y and Tsuneyoshi M. Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of β-catenin mutation in synovial sarcoma. J Pathol 2000;192:342-350.
17. Hasegawa T, Yokoyama R, Matsuno Y, Shimoda T and Hirohashi S. Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. Human Pathol 2001;32:257-263.
18. Billings SD, Walsh SV, Fisher C, Nusrat A, Weiss SW and Folpe AL. Aberrant expression of tight junction-related proteins ZO-1, claudin-1 and occluding in synovial sarcoma:an immunohistochemical study with ultrastructural correlation. Mod Pathol 2004;17:141-149.
19. Xie Y, Skytting B, Nilsson G, Gasbarri A, Haslam K, Bartolazzi A, Brodin B, Mandahl N and Larsson O. SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells:a gain of function of the t(X;18)(p11.2;q11.2) translocation. Cancer Res 2002;62:3861-3867.
20. Bolós V, Hector Peinado H, Pérez-Moreno MA, Fraga MF, Esteller M and Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions:a comparison with Snail and E47 repressors. J Cell Sci 2003;116:499-511.
21. Hajra KM, Chen DY and Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002;62:1613-1618.
22. Lubieniecka JM, de Bruijn DR, Su L, van Dijk AH, Subramanian S, van de Rijn M, Poulin N, van Kessel AG and Nielsen TO. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 2008;68:4303-4310.
23. Kanemitsu S, Hisaoka M, Shimajiri S, Matsuyama A and Hashimoto H. Molecular detection of SS18-SSX fusion gene transcripts by cRNA in situ hybridization in synovial sarcoma using formalin-fixed, paraffin-embedded tumor tissue specimens. Diagn Mol Pathol 2007;16:9-17.
24. Subramaniam MM, Navarro S and Llombart-Bosch A. Immunohistochemical study of correlation between histologic subtype and expression of epithelial-mesenchymal transition-related proteins in synovial sarcomas. Arch Pathol Lab Med 2011;135:1001-1009.
25. Martínez-Estrada OM, Cullerés A, Soriano FX, Peinado H, Bolós V, Martínez FO, Reina M, Cano A, Fabre M and Vilaró S. The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells. Biochem J 2006;394:449-457.
26. Parsons SL, Watson SA, Brown PD, Collins HM and Steele RJ. Matrix metalloproteinases. Br J Surg 1997;84:160-166.
27. Yang Y, Jiao L, Hou J, Xu C, Wang L, Yu Y, Li Y, Yang C, Wang X and Sun Y. Dishevelled-2 silencing reduces androgen-dependent prostate tumor cell proliferation and migration and expression of Wnt-3a and matrix metalloproteinases. Mol Biol Rep 2013;40:4241-50.
28. Kamino M, Kishida M, Kibe T, Ikoma K, Iijima M, Hirano H, Tokudome M, Chen L, Koriyama C, Yamada K, Arita K and Kishida S. Wnt-5a signaling is correlated with infiltrative activity in human glioma by inducing cellular migration and MMP-2. Cancer Sci 2011;102:540-548.
29. Saito T, Oda Y, Sakamoto A, Tamiya S, Iwamoto Y and Tsuneyoshi M. Matrix metalloproteinase-2 expression correlates with morphological and immunohistochemical epithelial characteristics in synovial sarcoma. Histopathology 2002;40:279-285.
30. Nagayama S, Katagiri T, Tsunoda T, Hosaka T, Nakashima Y, Araki N, Kusuzaki K, Nakayama T, Tsuboyama T, Nakamura T, Imamura M, Nakamura Y and Toguchida J. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 2002;62:5859-5866.
31. Segal NH, Pavlidis P, Antonescu CR, Maki RG, Noble WS, DeSantis D, Woodruff JM, Lewis JJ, Brennan MF, Houghton AN and Cordon-Cardo C. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 2003;163:691-700.
32. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y, Glatfelter AA, Duray PH and Meltzer PS. Gene expression profiling of human sarcomas:insight into sarcoma biology. Cancer Res 2005;65:9226-9235.
33. Ng TL, Gown AM, Barry TS, Cheang MC, Chan AK, Turbin DA, Hsu FD, West RB and Nielsen TO. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005;18:68-74.
34. Saito T, Nagai M, Tsuda M and Ladanyi M. Differentially expressed genes defined by expression profiling of sarcomas with chimeric transcription factors provide an enriched source of candidate transcriptional targets. Abstracts of LXX Cold Spring Harbor Symposium 2005;225.
35. Saito T, Oda Y, Yamamoto H, Kawaguchi K, Tanaka K, Matsuda S, Iwamoto Y and Tsuneyoshi M. Nuclear β-catenin correlates with cyclin D1 expression in spindle and pleomorphic sarcomas but not in synovial sarcoma. Hum Pathol 2006;37:689-697.
36. Saito T, Oda Y, Sakamoto A, Kawaguchi K, Tanaka K, Matsuda S, Tamiya S, Iwamoto Y and Tsuneyoshi M. APC mutations in synovial sarcoma. J Pathol 2002;196:445-449.
37. Brabletz T, Jung A, Dag S, Hlubek F and Kirchner T. β-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999;155:1033-1038.
38. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P and Matrisian LM. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumor. Oncogene 1999;18:2883-2891.
39. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW. Identification of c-myc as a target of the APC pathway. Science 1998;281:1509-1512.
40. Tetsu O and McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-426.
41. Hiendlmeyer E, Regus S, Wassermann S, Hlubek F, Haynl A, Dimmler A, Koch C, Knoll C, van Beest M, Reuning U, Brabletz T, Kirchner T and Jung A. β-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. Cancer Res 2004;64:1209-1214.
42. Conacci-Sorrell M, Simcha I, Ben-Yedidia T, Blechman J, Savagner P and Ben-Ze'ev A. Autoregulation of E-cadherin expression by cadherin-cadherin interactions:the roles of β-catenin signaling, slug, and MAPK. J Cell Biol 2003;163:847-857.
43. Pretto D, Barco R, Rivera J, Neel N, Gustavson MD and Eid JE. The synovial sarcoma translocation protein SYT-SSX2 recruits β-catenin to the nucleus and associates with it in an active complex. Oncogene 2006;25:3661-3669.